Clinical Trials Logo

Clinical Trial Summary

This is a clinical research study using I-131 Iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging devices. These images are used in diagnosing a variety of adrenal abnormalities.Prior to the injection of I-131 Iodocholesterol, the patient will receive perchlorate capsules to block any uptake of I-131 by the thyroid gland if this is deemed important. The patient will continue to take these capsules throughout the period of imaging, which may last up to 1 week. The injection of I-131 Iodocholesterol will be given into a vein and the patient will return for images on at least 1 and possibly 2 occasions between 3-7 days after injection. If the case requires it, the patient may also be given a steroid in tablet form, dexamethasone, to take orally prior to and after the injection to suppress normal adrenal function so that the abnormal tissues can be more easily detected.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT00037843
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Completed
Phase Phase 3
Start date December 1988
Completion date August 2007

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01465425 - Extracolonic Findings on Computed Tomography (CT) Colonography
Completed NCT02672020 - Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card N/A
Terminated NCT01348698 - Evaluation of Molecular Markers in Adrenal Tumors
Recruiting NCT02010957 - Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Phase 3